Dnajc9 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNAJC9 (DnaJ Heat Shock Protein Family (Hsp40) Member C9) is a co-chaperone protein that functions as a J-domain protein, assisting Hsp70 chaperones in protein folding, refolding, and targeting misfolded proteins for degradation. DNAJC9 plays important roles in cellular proteostasis, particularly in the nucleus and during stress responses .
| Property |
Value |
| Protein Name |
DNAJC9 / MRJ |
| Gene |
DNAJC9 |
| UniProt ID |
Q8WXX5 |
| Molecular Weight |
~37 kDa (335 amino acids) |
| Aliases |
MRJ, HSP40, DJC9 |
| Tissue Specificity |
Ubiquitous, higher in brain |
DNAJC9 contains several functional domains:
- J domain — Central domain that stimulates Hsp70 ATPase activity
- Gly/Phe-rich region — Flexible linker region
- C-terminal client-binding domain — Binds substrate proteins
- Nuclear localization signals — Targets protein to nucleus
As a co-chaperone, DNAJC9:
- Partners with Hsp70 proteins (particularly HSPA1A/Hsp70-1 and HSPA8/Hsc70)
- Facilitates protein folding by recruiting clients to Hsp70
- Helps refold denatured proteins
- Prevents protein aggregation during stress
DNAJC9 has several nuclear roles:
- Chromatin remodeling — Associates with histone deacetylase complexes
- Transcription regulation — Modulates transcriptional activity
- DNA repair — Involved in DNA damage response pathways
- Ribosome biogenesis — Participates in ribosome assembly
In the nervous system, DNAJC9 is expressed in:
- Neurons (cortical, hippocampal)
- Glial cells
- High expression in regions involved in learning and memory
DNAJC9 involvement in neurodegeneration:
- Alzheimer's Disease — May help clear misfolded tau and amyloid
- Parkinson's Disease — Potential role in alpha-synuclein handling
- Huntington's Disease — May assist in mutant huntingtin clearance
- Amyotrophic Lateral Sclerosis — Protein aggregation management
DNAJC9 dysregulation in cancer:
- Overexpression in certain leukemias
- Potential oncogenic activity
- Interaction with HDAC complexes
Key partners of DNAJC9:
- HSPA1A — Hsp70-1, major Hsp70 partner
- HSPA8 — Hsc70, constitutive Hsp70
- HDAC1/2 — Histone deacetylases
- CK2 — Casein kinase 2 (phosphorylates DNAJC9)
- Ubiquitin-proteasome components
Targeting DNAJC9 for therapy:
- Enhancing co-chaperone activity to boost protein clearance
- Modulating Hsp70/DNAJC complexes for aggregate clearance
- Combination with Hsp90 inhibitors
The study of Dnajc9 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.